Keyphrases
Hyperactivity
100%
Social Isolation
100%
Pharmacological Characterization
100%
Schizophrenia
27%
Socially Isolated
27%
Second-generation Antipsychotics
27%
Prepulse Inhibition Deficit
27%
Group-housed
18%
Antipsychotics
18%
Current Treatment
9%
After Weaning
9%
Prepulse Inhibition
9%
Receptor Agonist
9%
Postnatal Day
9%
Non-pharmacological
9%
Haloperidol
9%
Behavior Modification
9%
Screening Assays
9%
Glutamate Receptors
9%
In Vivo Screening
9%
Risperidone
9%
Olanzapine
9%
Neurodevelopmental Hypothesis
9%
Neuroscience
Social Isolation
100%
Hyperactivity
100%
Prepulse Inhibition
36%
Antipsychotic
36%
Risperidone
9%
Receptor Agonists
9%
Haloperidol
9%
In Vivo
9%
Olanzapine
9%
Glutamate Receptor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Hyperactivity
100%
Antipsychotic
36%
Olanzapine
9%
Glutamate Receptor Agonist
9%
Risperidone
9%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
9%